There is a need to ascertain the type and level of treatment burden experienced by people with co-morbidities. This is important to identify the characteristics of participants who are at most risk of treatment burden.
The aim of this study is to identify the characteristics of participants who are at most risk of treatment burden.
This cross-sectional study was part of a larger project and recruitment was conducted across four Australian regions: rural, semi-rural and metropolitan. Participants were asked about their treatment burden using an adapted version of a measure, which included the following five dimensions: medication, time and administrative, lifestyle change, social life and financial burden.
In total, 581 participants with various chronic health conditions reported a mean global treatment burden of 56.5 out of 150 (standard deviation = 34.5). Number of chronic conditions (β = .34, p < 0.01), age, (β = −.27, p < 0.01), the presence of an unpaid carer (β = .22, p < 0.001) and the presence of diabetes mellitus and other endocrine conditions (β = .13, p < 0.01) were significant predictors of overall treatment burden. For the five dimensions of treatment burden, social, medicine and administrative burden were predicted by the same cluster of variables: number of conditions, age, presence of an unpaid carer and diabetes. However, in addition to these variables, financial dimensions were also predicted by education level, ethnicity and health insurance. Educational level also influenced lifestyle burden.
A substantial proportion of community-dwelling adults with chronic conditions have considerable levels of treatment burden. Specifically, health professionals should provide greater focus on managing overall treatment burden for persons who are of young age, have an endocrine condition or an unpaid carer, or a combination of these factors.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Tax calculation will be finalised during checkout.
A government concession whereby the cost of prescription medicines for individuals and families is reduced once the PBS Safety Net threshold has been reached.
Tran V-T, Montori VM, Eton DT, Baruch D, Falissard B, Rvaud P. Development and description of measurement properties of an instrument to assess treatment burden among patients with multiple chronic conditions. BMC Med. 2012;10(68):1–10.
Mair FS, May CR. Thinking about the burden of treatment. BMJ. 2014;349:1–2.
Gallacher K, Morrison D, Jani B, Macdonald S, May CR, Montori VM, et al. Uncovering treatment burden as a key concept for stroke care: a systematic review of qualitative research. PLoS Med. 2013;10:1–17.
Tran V-T, Barnes C, Montori V, Falissard B, Ravaud P. Taxonomy of the burden of treatment: a multi-country web-based qualitative study of patients with chronic conditions. BMC Med. 2015;131:115.
Demain S, Gonçalves A-C, Areia C, Oliveira R, Marcos AJ, Marques A, et al. Living with, managing and minimising treatment burden in long term conditions: a systematic review of qualitative research. PLoS One. 2015;1:e0125457.
Sav A, Kendall E, McMillan SS, Kelly F, Whitty JA, King MA, et al. ‘You say treatment, I say hard work’: treatment burden among people with chronic illness and their carers in Australia. Health Soc Care Commun. 2013;21:665–74.
Moss L, Crane PB. Exploring polypharmacy in elderly women after myocardial infarction. J Women Aging. 2010;22:22–33.
Eton DT, Oliveira OR, Egginton JS, Odell L, May CR, Montori VM. Building a measurement framework of burden of treatment in complex patients with chronic conditions: a qualitative study. Patient Relat Outcome Meas. 2012;3:39–49.
May C, Montori VM, Mair FS. We need minimally disruptive medicine. BMJ. 2009;339:485–7.
Sav A, King MA, Whitty JA, Kendall E, McMillan SS, Kelly F, et al. Burden of treatment for chronic illness: a concept analysis and review of the literature. Health Expect. 2015;18:312–24.
Sav A, McMillan SS, Kelly F, Kendall E, Whitty JA, King MA, et al. Treatment burden among people with chronic illness: what are consumer health organizations saying? Chronic Illness. 2013;9:220–32.
Eton DT, Elraiyah TA, Yost KJ, Ridgeway JL, Johnson A, Egginton JS, et al. A systematic review of patient-reported measures of burden of treatment in three chronic diseases. Patient Relat Outcome Meas. 2013;4:7–20.
Hyland M, Whalley B, Jones R, Masoli M. A qualitative study of the impact of severe asthma and its treatment showing that treatment burden is neglected in existing asthma assessment scales. Qual Life Res. 2015;24:631–9.
Caughey G, Vitry A, Gilbert A, Roughead E. Prevalence of comorbidity of chronic diseases in Australia. BMC Public Health. 2008;8:221.
Australian Institute of Health and Welfare. Australian Burden of Disease Study: fatal burden of disease 2010. Canberra: Australian Institute of Health and Welfare; 2015.
Whitty JA, Kendall E, Sav A, Kelly F, McMillan SS, King MA, et al. Preferences for the delivery of community pharmacy services to help manage chronic conditions. Res Soc Adm Pharm. 2015;11:197–215.
Tran V-T, Harrington M, Montori V, Barnes C, Wicks P, Ravaud P. Adaptation and validation of the Treatment Burden Questionnaire (TBQ) in English using an internet platform. BMC Med. 2014;12:109.
Australian Bureau of Statistics. National Health Survey 2007–2008. Canberra: Australian Bureau of Statistics; 2013.
Bohlen K, Scoville E, Shippee ND, May CR, Montori VM. Overwhelmed patients: a videographic analysis of how patients with type 2 diabetes and clinicians articulate and address treatment burden during clinical encounters. Diabet Care. 2012;35:47–9.
Bernhard J, Maibach R, Thurlimann B, Sessa C, Aapro MS. Patients’ estimation of overall treatment burden: why not ask the obvious? J Clin Oncol. 2002;20:65–72.
We thank all participants for completing the survey. We are grateful to Beth Hunter, Rhonda Knights, Nicholas Moir, Brittany Williams and community leaders who supported us in recruiting participants. We thank Gabor Mihala for assistance with data management and Jean Spinks for support with data analysis.
This project was funded by the Australian Government Department of Health as part of the Fifth Community Pharmacy Agreement Research and Development Programme managed by The Pharmacy Guild of Australia. The financial assistance provided must not be taken as endorsement of the contents of this study.
AS, JAW, SM, EK, FK, MAK and AJW declare that they have no competing interests.
Approval for this study was obtained from a University Human Ethics Committee (PHM/12/11/HREC), and from one state Government Health Department. Informed consent was obtained from all individuals who participated in the study. Thus study was conducted in accordance with the World Medical Association’s Declaration of Helsinki.
About this article
Cite this article
Sav, A., Whitty, J.A., McMillan, S.S. et al. Treatment Burden and Chronic Illness: Who is at Most Risk?. Patient 9, 559–569 (2016). https://doi.org/10.1007/s40271-016-0175-y
- Chronic Condition
- Financial Burden
- Endocrine Condition
- Private Health Insurance
- Stepwise Multiple Regression